Halozyme Therapeutics, Inc.
HALO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,015,324 | $829,253 | $660,116 | $443,310 |
| % Growth | 22.4% | 25.6% | 48.9% | – |
| Cost of Goods Sold | $159,417 | $192,361 | $139,304 | $81,413 |
| Gross Profit | $855,907 | $636,892 | $520,812 | $361,897 |
| % Margin | 84.3% | 76.8% | 78.9% | 81.6% |
| R&D Expenses | $79,048 | $76,363 | $66,607 | $35,672 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $154,335 | $149,182 | $143,526 | $50,323 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $71,049 | $73,773 | $43,148 | $0 |
| Operating Expenses | $304,432 | $299,318 | $253,281 | $85,995 |
| Operating Income | $551,475 | $337,574 | $267,531 | $275,902 |
| % Margin | 54.3% | 40.7% | 40.5% | 62.2% |
| Other Income/Exp. Net | $5,657 | $10,755 | -$18,613 | -$27,384 |
| Pre-Tax Income | $557,132 | $348,329 | $248,918 | $248,518 |
| Tax Expense | $113,041 | $66,735 | $46,789 | -$154,192 |
| Net Income | $444,091 | $281,594 | $202,129 | $402,710 |
| % Margin | 43.7% | 34% | 30.6% | 90.8% |
| EPS | 3.5 | 2.13 | 1.48 | 2.86 |
| % Growth | 64.3% | 43.9% | -48.3% | – |
| EPS Diluted | 3.43 | 2.1 | 1.44 | 2.74 |
| Weighted Avg Shares Out | 126,827 | 131,927 | 136,844 | 140,646 |
| Weighted Avg Shares Out Dil | 129,424 | 134,197 | 140,608 | 146,796 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $18,095 | $18,762 | $16,947 | $7,526 |
| Depreciation & Amortization | $81,312 | $84,856 | $49,641 | $2,997 |
| EBITDA | $656,539 | $451,947 | $315,506 | $259,041 |
| % Margin | 64.7% | 54.5% | 47.8% | 58.4% |